Objective: The objective of our study was to quantify the arteriogenic potency of Monocyte Chemoattractant Protein-1 (MCP-1) under hyperlipidemic conditions. Additionally, we aimed to determine the effects of locally applied MCP-1 on systemic serum lipid levels as well as on atherosclerosis. Methods: A total of sixty-four Watanabe rabbits was treated with either low dose MCP-1 (1 mg / kg / week), high dose MCP-1 (3.3 mg / kg / week) or PBS as a control substance. Substances were applied directly into the collateral circulation via an osmotic minipump with the catheter placed in the proximal stump of the ligated femoral artery. Either 1 week or 6 months after initiation of the treatment X-ray angiography was performed as well as measurements of collateral conductance using fluorescent microspheres. The extent of atherosclerosis was quantified in whole aortas using Sudan IV staining. Results: One week after ligation of the femoral artery a significant increase in collateral conductance was observed in animals treated with high dose MCP-1 (control: 2.260.8 ml / min / 100 mmHg vs. MCP-1 high dose: 8.962.0 ml / min / 100 mmHg, P , 0.05). Six months after femoral artery ligation no differences were found between the treated and the control group (PBS; 44.9611.6 ml / min / 100 mmHg, MCP-1; 47.8611.5 ml / min / 100 mmHg, P5NS). No influence was found on serum lipids or on the development of atherosclerosis in the present model. Conclusion: MCP-1 accelerates arteriogenesis upon femoral artery ligation under hyperlipidemic conditions. Six months after treatment these pro-arteriogenic effects of MCP-1 can no longer be observed. The present data do not show an effect of local MCP-1 treatment on serum lipids or on atherosclerosis. It should be noted however that a high standard deviation was observed for the data on atherosclerotic surface area, necessitating additional experiments in a different model of atherosclerosis.
1 . Introduction new therapeutic modality to treat peripheral and coronary obstructive arterial disease [2] . Monocyte Chemoattractant Protein 1 (MCP-1) signifiHowever, it is not known whether the arteriogenic cantly increases the process of arteriogenesis when locally properties of MCP-1 are preserved in a hyperlipidemic applied in a rabbit hindlimb model of femoral artery environment. Moreover, arteriogenesis and atherogenesis occlusion [1] . The arteriogenic action of MCP-1 is thought display several similarities like monocyte infiltration, to be based on an increased number of attracted monocytes increased expression of growth factors and cytokines and to the place of interest and this factor holds promise as a smooth muscle cell mitosis. Therefore, a possible limitation to every arteriogenic therapy is the acceleration or initiation of atherosclerotic lesion development. This is an even more realistic potential side-effect when using MCP-2 .2. Serum levels of lipids 1 as arteriogenic substance, since this cytokine is believed to be directly involved in the initiation of atherogenesis A total of 2 ml blood was withdrawn from the ear vein [3] .
shortly before sacrifice. Triglycerides, total cholesterol, The Watanabe Heritable Hyper-Lipidemic (WHHL) VLDL, LDL and HDL were then measured enzymatically rabbit possesses an inheritable deficiency of LDL rein serum. ceptors, similar to familiar hypercholesterolemia in humans, leading to high LDL plasma levels and early 2 .3. X-ray angiography development of atherosclerosis [4, 5] . We used this animal model to study the short-and long-term effects of locally From group I to V a total of 6 animals per group was applied MCP-1 on both atherogenesis and arteriogenesis randomly selected for X-ray angiography. After sacrifice under hyperlipidemic conditions. Additionally we deterof the animals a canula was inserted into the abdominal mined the effects of MCP-1 treatment on serum lipid aorta and a bismuth / gelatine contrast was slowly infused levels.
under constant pressure of 80 mmHg. Animals were then put on ice for 2 h. control: n56) after femoral artery ligation, measurements was performed to visualize and ligate the right femoral of collateral conductance were performed as previously artery. A catheter with the tip being placed upstream in the described [6] . In short: the left and right arteria saphena proximal stump of the occluded artery was connected to an magna were canulated with sterile polyethylene heparinosmotic minipump (Alzet, 2ML1, Alza Corp., Palo Alto, ized catheters for peripheral pressure measurements. The USA). Thereby the substance was directly delivered into left femoral artery was canulated for microsphere reference the collateral circulation for a defined time period of 1 sampling. A pump-driven shunt, installed in the abdominal week. The absence of any residual volume in the aorta, ensured oxygenated blood flow from the carotid minipumps (,3%) after the experiment verified delivery artery in the abdominal aorta into the right and left of the contents. Twelve animals were treated with a total hindlimbs. Additionally, donor blood was used from MCP-1 dose of 1 mg / kg (low dose), 24 animals were animals that were selected for X-ray angiography. A threetreated with a total MCP-1 dose of 3.3 mg / kg (high dose) way stopcock was attached to the aortic canula in order to and 24 animals received Phosphate Buffered Saline (PBS) measure pressure at the level of the abdominal aorta, distal as a control substance. Animals were then divided in six from the shunt. An in-line flow probe (Transonics, Ithaca, groups. Group I consisted of 12 animals treated with low NY, USA) was installed in the shunt system for measuredose MCP-1 and analyzed after 1 week, group II consisted ments of total flow to both hindlimbs. of 12 animals treated with high dose MCP-1 and analyzed Maximal vasodilatation was achieved by injecting after 1 week, group III consisted of 12 animals treated with adenosine to the shunt at a constant rate of 1 mg / kg / min. PBS and analyzed after 1 week, group IV consisted of 12 After stabilization of peripheral and central pressures, both animals treated with high dose MCP-1 and analyzed after 6 legs were perfused via the aortic canula at six different months and group V consisted of 12 animals treated with pressures. The six perfusion pressure levels were generated PBS and analyzed after 6 months. The sixth group in vivo with a roller pump, installed in line with the shunt consisted of 4 non-operated animals that were used to between carotid artery and abdominal aorta. For each obtain normal values of collateral conductance in WHHL pressure level, 15 mm microspheres (Molecular Probes, rabbits. Age of the animals at the time of the operation was Eugene, Oregon, USA) with each a different fluorescent either 6 months or 1 year, divided over the groups in such color were injected into the mixing chamber, that was a way that for the final experiment each animal was around installed in the carotid-abdominal aortic shunt system. For 1 year. Animals weighed between 2.4 and 3.3 kg.
each colour a total of 2 million microspheres was injected, ensuring a large enough amount of microspheres in the 3 .2. X-ray angiography individual tissue samples. The amount of microspheres in hindlimb tissue was then quantified using FACS-analysis One week after ligation several collateral arteries could (Becton Dickinson and Co, Lincoln Park, NJ, USA). Flows be observed, spanning mainly from the arteria profunda to for each hindlimb sample were then calculated from the the arteria genualis and the arteria saphena parva. The number of microspheres in the tissue, the microsphere number of visible collateral vessels was 12.662.3 in the count in the reference sample, the internal standard in the WHHL rabbit control group. The low dose MCP-1 group sample, the internal standard in the reference sample, the did not differ significantly from the control group weight of the reference sample and the time-interval in (14.363.4). The 1-week treatment with high dose MCP-1 which the reference sample is withdrawn. For each prescaused a significant increase in the number of visible sure step the difference between peripheral and central collateral vessels (19.462.4, P , 0.05 / 3 as compared to pressure was calculated. Collateral conductance was then the control group). Six months after femoral artery ligation retrieved from the slope of the curve of flow and pressure the number of visible arteries had regressed in both groups difference.
(a process referred to as 'pruning') showing no longer a difference in the number of visible collateral arteries between the high-dose MCP-1 treated group and the 2 .5. Quantification of atherosclerotic plaque formation control group (MCP-1; 8.260.9, PBS; 7.560.8, P5NS, Figs. 1 and 2). Complete aortas were isolated, embedded in formalin 4% and stained with Sudan IV. After the staining pro-3 .3. Collateral conductance measurements cedure, a planimetric quantification of the percentage of atherosclerotic plaque was performed from digitized photo-
The normal value for collateral conductance in the graphs using NIH Image software (available on the internet WHHL rabbit was 76.066.6 ml / min / 100 mmHg. One as shareware, http: / / rsb.info.nih.gov / nih-image).
week after femoral artery ligation, collateral conductance was 2.260.8 ml / min / 100 mmHg. In the low dose MCP-1 2 .6. Statistical analysis group no significant increase in collateral conductance could be observed (3.461.6 ml / min / 100 mmHg, P5NS Results are presented as mean6standard deviation.
as compared to the control group). However, treatment Significant differences between sample means were dewith high dose MCP-1 significantly increased collateral termined with an independent-samples T-test. Differences conductance, 1 week after femoral artery ligation (8.962 .0 with a p-value ,0.05 were classified as significant. ml / min / 100 mmHg, P , 0.05 / 3 as compared to the However, when more than two groups were compared, a control group). Bonferroni correction was performed and the level of Six months after femoral artery ligation a restoration of significance was lowered to 0.05 divided by the number of flow to approximately 60% of normal was found in both groups.
the treated as well as the control group. At this time-point the difference in collateral conductance between the MCP-1 treated animals and the control animals was no longer 3 . Results significant (PBS; 44.9611.6 ml / min / 100 mmHg, MCP-1; 47.8611.5 ml / min / 100 mmHg, P5NS, Fig. 3 ). 3 .1. Serum levels of lipids 3 .4. Quantification of atherosclerotic plaque formation High levels of serum lipids were observed in both the control groups as well as in the MCP-1 treated groups.
Aortas of both treated and control WHHL rabbits However, no significant differences were observed beshowed massive plaque formation. Plaque formation was tween any of the groups for values of either cholesterol, especially strong in the aortic arch and was found to a triglycerides, HDL or LDL neither at 1 week after the lesser extent in the thoracical and abdominal aorta (Fig. 4) . treatment (see Table 1 ) nor at 6 months after treatment However, no significant differences were found between (data not shown).
the control and the MCP-1 treated group in percentage of atherosclerotic plaque / total endoluminal wall, 6 months conditions in the Watanabe rabbit. However, the effects are after femoral artery ligation (control; 26.1618.1%, vs.
somewhat diminished as compared to the effects in normal MCP-1; 33.5614.4% P5NS, Fig. 5 ).
New Zealand White Rabbits [6] and higher dosages of MCP-1 are required to elicit an arteriogenic response. There was no longer an effect seen on the conductance of 4 . Discussion the collateral circulation 6 months after the treatment. The treatment with either low or high dose MCP-1 had no The main finding of our study is that the arteriogenic effect on serum lipids. Moreover, using Sudan IV staining potency of MCP-1 is preserved under hyperlipidemic we could not detect a statistical significant difference in the accelerated arteriogenic response was found, increasing collateral conductance approximately 4-fold, 1 week after femoral artery ligation. The salutory effect of high dose MCP-1 treatment on collateral conductance was no longer detectable 6 months after treatment. This indicates that the MCP-1 dose that was used in the present study induces an acceleration of the natural arteriogenic response upon femoral artery ligation but diminishes over time. It is currently not known whether final effects on collateral conductance can be altered by either higher dosages of MCP-1 or the combination of MCP-1 with other arteriogenic growth factors like TGF-b or b-FGF [9] [10] [11] . This is of interest in view of earlier findings showing that the combination of MCP-1 and GM-CSF in a chronic model of more matured collater- In Fig. 6 we have made a direct comparison between development of atherosclerotic plaques between MCP-1 Watanabe and NZW rabbits for both absolute values of treated animals and control animals, 6 months after conductance as well as for the percentages of normal initiation of the treatment. It should be noted however that conductance. The latter correction is important since in the standard deviation of the data derived with the Sudan WHHL rabbits normal conductance without femoral artery IV staining were of such magnitude that a potential proligation was about 45% of the conductance that we atherogenic effect of MCP-1 cannot be excluded based on observed in normal rabbits of equal weight [6] . It has been these data.
shown previously that the responsiveness of the rabbit Hyperlipidemia negatively influences the arteriogenic hindlimb resistance vasculature to adenosine is not improperties of MCP-1 in WHHL rabbits. The WHHL rabbits paired by hypercholesterolemia [13] . Thus, the increased were treated with an MCP-1 dose that was shown in a peripheral resistance in WHHL rabbits (and thus the previous study to significantly increase arteriogenesis in decreased conductance) most probably is due to the normal New Zealand White (NZW) rabbits [6] . Additionatherosclerotic disease itself [14] . The NZW rabbit data ally, a group was treated with a higher dose of MCP-1 presented in Fig. 6 are previously published historical data, since it has been described previously that collateral except for the high dose MCP-1 treatment [6] . The formation is diminished under hyperlipidemic conditions measurements of collateral conductance were performed [7, 8] . Indeed we could show that the low dose MCP-1 under exactly the same conditions as described for the treatment, that is sufficient to induce a strong arteriogenic current manuscript. As shown, low-dose MCP-1 treatment response in NZW rabbits, has no significant arteriogenic significantly increases collateral conductance in NZW effect in WHHL rabbits. In the high dose MCP-1 group an rabbits, in contrast to the lack of arteriogenic efficacy in Fig. 6 . Comparison between Watanabe and NZW rabbits for either absolute conductance values (6A) or percentages of normal conductance (6B). As shown clearly, the arteriogenic effects of MCP-1 are significantly reduced in Watanabe rabbits compared to normal NZW rabbits (* indicates a p-value lower than 0.05).
Watanabe rabbits. In the high dose MCP-1 group an in mice [24, 25] . In addition, in irradiated apoE-deficient accelerated arteriogenic response was found in both mice that were repopulated with bone marrow cells from Watanabe as well as NZW rabbits. However, the 4-fold MCP-1 transgenic mice, the localized overexpression of increase in percentage of normal conductance in Watanabe MCP-1 by macrophages resulted in amplification of rabbits is still a diminished response as compared to the atherosclerosis [26] . Therefore, additional insight into the 9-fold increase as observed upon high dose MCP-1 treatpro-atherogenic properties of MCP-1 when applied as a ment in New Zealand White rabbits. In the PBS-treated pro-arteriogenic substance are mandatory prior to the control groups a significant difference in arteriogenic initiation of a clinical trial. The route of administration of response was found between Watanabe and NZW rabbits MCP-1 in such a clinical study should preferably be local only for absolute conductance values (Fig. 6A) .
and intra-arterial since this form of application most The potential of angiogenic or arteriogenic substances to efficiently restores perfusion upon arterial obstruction [27] stimulate atherogenesis is a topic that requires careful and may limit systemic side-effects. attention [15] . Barger first proposed that angiogenesis, i.e.
In the WHHL rabbits, the atherosclerotic plaque surface the formation of new capillary networks via endothelial in the aorta was not significantly increased upon high dose sprouting, is an integral part of atherosclerotic plaque MCP-1 treatment as compared to the control animals 6 formation [16] . Subsequently, Folkman showed that the months after the 1-week treatment. However, these data inhibition of angiogenesis via TNP-470 or endostatin are somewhat difficult to interpret. It should be noted that a diminishes plaque formation [17] . More recently it was trend could be recognized towards more atherosclerotic shown by Celletti et al. that the exogenous application of a plaque surface in the MCP-1 treated animals (26.1 vs. low dose of the angiogenic factor Vascular Endothelial 33.5%). This difference did by no means reach statistical Growth Factor (VEGF) stimulates plaque formation in significance ( p-value of 0.32) but this might also be due to both cholesterol-fed rabbits and knock-out mice, doubly the relatively high standard deviation that was observed in deficient in apolipoprotein E / apolipoprotein B100 [18] . both groups. It could still be postulated that this large Arteriogenesis, i.e. the transformation of small pre-existvariety within the groups masks the pro-atherogenic effects ing vascular collateral pathways into large-sized collateral of high dose MCP-1. conductance arteries, plays no direct role during
In conclusion, it was found that MCP-1 elicits an atherogenesis. However, arteriogenesis and atherogenesis arteriogenic response, even under severe hyperlipidemic share numerous common features. Shear stress upregulates conditions as observed in WHHL rabbits. The dosage the expression of endothelial cell adhesion receptors [19] required for the arteriogenic response is however 3-fold and this occurs during both atherogenesis and arhigher as compared to the dosage needed under norteriogenesis [20] [21] [22] . Also the subsequent monocyte / molipidemic conditions. Treatment with MCP-1 did not macrophage invasion plays a pivotal role in both arinfluence serum lipids and in the present model we did not teriogenesis and atherogenesis. Other features shared by detect a pro-atherogenic effect of MCP-1. However, in arteriogenesis and atherogenesis include smooth muscle order to be able to definitely exclude pro-atherogenic cell mitosis and elastolysis.
side-effects of MCP-1 when used as a pro-arteriogenic During flow-restoration upon arterial obstruction, monosubstance, more studies are warranted in different models cytes act in a pro-arteriogenic fashion. The endothelial of atherosclerosis. expression of ICAM-1, an adhesion molecule for monocytes, is increased early during arteriogenesis and, using electron-microscopy and immuno-histochemistry, sub-A cknowledgements sequently large numbers of adhering monocytes and perivascular macrophages are observed. These perivascular
We gratefully acknowledge the expert statistical assismacrophages produce several growth factors, like basic tance of Professor J.G.P. Tijssen. Fibroblast Growth Factor and Tumour Necrosis Factor alpha, required for the transformation of pre-existent collateral arterioles into large conductance arteries [23] .
However, in contrast to their beneficial pro-arteriogenic R eferences capacity it is believed that monocytes play a detrimental role during atherogenesis, leading for example to weaken- 
